Linear and conformational B cell epitope prediction of the HER 2 ECD-subdomain III by in silico methods

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3053-3059

  Mahdavi, Manijeh ^a   Mohabatkar, Hassan ^b   Keyhanfar, Mehrnaz ^b   Dehkordi, Abbas Jafarian ^a   Rabbani, Mohammad ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF ISFAHAN   (Iran)

Author keywords

Bioinformatics; Cancer therapy; Conformational B cell epitope; HER2 receptor; Peptide vaccine

Indexed keywords

EID: 84873599173     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3053     Document Type: Article

References (49)

1. Ansari HR, Gajendra PS, Raghava GP (2010). Identification of conformational B-cell epitopes in an antigen from its primary sequence. Immunol Res, 6, 6.
2. Bonilla FA, Oettgen HC (2010). Adaptive immunity. J Allergy Clin Immunol, 125, 33-40.
3. Boyer CM, Pusztai L, Wiener JR, et al. (1999). Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbb-2 (her-2/neu) gene product p185. Int J Cancer, 82, 525-31.
4. Bradford JR, Westhead DR (2005). Improved prediction of protein-protein binding sites using a support vector machines approach. Bioinform, 21, 1487-94.
5. Calabrich A, Fernandes GS, Katz A (2008). Trastuzumab: mechanisms of resistance and therapeutic opportunities. Oncol (Williston Park), 22, 1250-8.
6. Chen P, Rayner S, Hu KH (2011). Advances of Bioinformatics tools applied in virus epitopes prediction. Virologica sinica, 26, 1-7.
7. Cho HS, Mason K, Ramyar KX, et al. (2003). Structure of the extracellular region of HER2 alone and in complex with the herceptin fab. Nature, 421, 756-60.
8. Dakappagari NK, Lute KD, Rawale S, et al. (2005). Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J Biol Chem, 280, 54-63.
9. Dakappagari NK, Pyles J, Parihar R, et al. (2003). Chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol, 170, 4242-53.
10. Dakappagari N, Douglas D, Triozzi P, et al. (2000). Prevention of mammary tumors with a chimeric Her-2 B-cell epitope peptide vaccine. Cancer Res, 60, 3782-9.
11. Disis ML, Cheever MA (1997). HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res, 71, 343-71.
12. Ercolini AM, Machiels JP, Chen YC, et al. (2003). Identification and character-ization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol, 170, 4273-80.
13. Fiore PD (1987). ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 237, 178-82.
14. Franklin MC, Carey KD, Vajdos FF, et al. (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell, 5, 317-28.
15. Garrett JT, Kaumaya P, Pei D, et al. (2007). Peptide based B cell epitope vaccines targeting HER-2/Neu. Degree of doctor of philosophy thesis in the graduate school of the Ohio State University.
16. Goede A, Jaeger IS, Preissner R (2005). SUPERFICIAL-surface mapping of proteins via structure-based peptide library design. BMC Bioinform, 6, 223.
17. Haro I, Gomara MJ (2004). Design of synthetic peptidic constructs for the vaccine development against viral infections. Curr Protein Pept Sci, 5, 425-33.
18. Haste Andersen P, Nielsen M, Lund O (2006). Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci, 15, 2558-67.
19. Ishida T, Tsujisaki M, Hinoda Y, et al. (1994). Establishment and characterization of mouse-human chimeric MAb to erbB-2 product. Jpn J Cancer Res, 85, 172-8.
20. Jasinska J, Wagner S, Radauer C, et al. (2003). Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of HER- 2/Neu. Int J Cancer, 107, 976-83.
21. Jiang L, Zhou JM, Yin Y, et al. (2010). Selection and identification of B-cell epitope on NS1 protein of dengue virus type 2. Virus Res, 150, 49-55.
22. Kulkarni-Kale U, Bhosle S, Kolaskar AS (2005). CEP: a conformational epitope prediction server. Nucleic Acids Res, 33, 168-71.
23. Larsen JE, Lund O, Nielsen M (2006). Improved method for predicting linear B cell epitopes. Immunol Res, 2, 2.
24. Lax I (1988). Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Bio, 8, 1831-4.
25. Lebreton A, Moreau V, Lapalud P, et al. (2011). Discontinuous epitopes on the C2 domain of coagulation factor VIII mapped by computer-designed synthetic peptides. Brit J Hem, 155, 487-97.
26. Manzalawy Y, Dobbs D, Honavar V (2008b). Predicting flexible length linear B-cell epitopes. 7th international conference on computational systems bioinformatics. CA. 121-31.
27. Manzalawy Y, Dobbs D, Honavar V (2008a). Predicting linear B-cell epitopes using string kernels. J Mol Rec, 21, 243-55.
28. Michalsky E, Goede A, Preissner R (2003). Loops In Proteins (LIP)-a comprehensive loop database for homology modelling. Protein Eng, 16, 979-85.
29. Mittelman A, Lucchese A, Sinha A, Kanduc D (2002). Monoclonal and polyclonal humoral immune response to EC HER-2/Neu peptides with low similarity to the host,s proteome. Int J Cancer, 98, 741-7.
30. Miyako H, Kametani Y, Katano I, et al. (2011). Antitumor Effect of New HER2 peptide vaccination based on B cell epitope. Anticancer Res, 31, 3361-8.
31. Montgomery R, Makary E, Schiffman K, et al. (2005). Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal regulated kinase. Cancer Res, 65, 650-6.
32. Moreau V, Fleury C, Piquer D, et al. (2008). PEPOP: computational design of immunogenic peptides. BMC Bioinform, 9, 71.
33. Park JW (2008). Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer, 8, 392-401.
34. Pietras RJ (1995). HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene, 10, 2435-46.
35. Ponomarenko J, Bui HH, Li W, et al. (2008). ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinform, 9, 514.
36. Richard A, Goldsby T, Kindt J, et al. (2000). Kubey Immonology. 5th ed. (W H Freeman and Co (Sd)).
37. Rockberg J, Schwenk JM, Uhlén M (2009). Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies. Mol onco, 3, 238-47.
38. Saha S, Raghava GP (2004) BcePred:Prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. In: Nicosia G, Cutello V, Bentley PJ, Timis J, eds. ICARIS, Springer. Heidelberg. pp 197-204.
39. Saha S, Raghava GP (2006). Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins, 65, 40-8.
40. Sakaguchi S (2000). Regulatory T cells: key controllers of immunologic selftolerance. Cell, 101-455.
41. Siyi H, Zhiqiang Z, Liangwei L, et al. (2008). Epitope mapping and structural analyses of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Proteins, 70, 938-49.
42. Tai W, Mahato R, Cheng K (2010). The role of HER2 in cancer therapy and targeted drug delivery-Review. J Control Rel, 146, 264-75.
43. Veje Axelsena T, Holma A, Christiansena G, et al. (2011). Identification of the shortest AB-peptide generating highly specific antibodies against the C-terminal end of amyloid-B42. Vaccine, 29, 3260-9.
44. Vita R, Zarebski L, Greenbaum JA, et al. (2010). The immune epitope database 2.0. Nucleic Acids Res, 38, 854-62.
45. Wang C, Li Y, Li P (2000). Generation and Characterization of monoclonal antibodies specific for the oncogene product P185 neu/c-erbB-2 by surface epitope masking (SEM). J Chin Immunol, 16, 539-41.
46. Wang JN, Feng JN, Yua M, et al. (2004). Structural analyses of the epitopes on erbB2 interacted with inhibitory or non-inhibitor monoclonal antibodies. Mol Immunol, 40, 963-9.
47. Wiwanitkit V (2007). Predicted B-cell epitopes of HER-2 oncoprotein by a bioinformatics method: a clue for breast cancer vaccine development. Asian Pac J Cancer Prev, 8, 137-8.
48. Yum LY, Robyn LW (2002). Anti-ErbB2 monoclonal antibodies and ErbB2-directed vaccines. Cancer Immunol Immunother, 50, 569-87.
49. Zhang W, Xiong Y, Zhao M, et al. (2011). Prediction of conformational B-cell epitopes from 3D structures by random forests with a distance-based feature. BMC Bioinform, 12, 341.